Research programme: receptor tyrosine kinase inhibitors - SignalChem Lifesciences
Alternative Names: SLC-500; SLC-500 program - SignalChem LifesciencesLatest Information Update: 03 Oct 2023
At a glance
- Originator SignalChem Lifesciences
- Class Antineoplastics; Small molecules
- Mechanism of Action RON protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 26 Sep 2023 Receptor tyrosine kinase inhibitors are available for licensing as of 26 Sep 2023 (SignalChem Lifesciences website, September 2023)
- 22 Sep 2023 Early research in Solid tumours in Canada (unspecified route) prior to September 2023 (SignalChem Lifesciences pipeline, September 2023)